N4 Pharma encouraging data, oncology the quickest route to clinic (Interview)

N4 Pharma plc (LON:N4P) CEO Nigel Theobald joins DirectorsTalk to discuss encouraging data from its oncology research.

Nigel describes the behavior of Nuvec, explains why now a focus on oncology, work on vaccines, funding and what investors can expect over the coming months.

N4 Pharma is a the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines.

Find more news, interviews, share price & company profile here for:

    Share this interview

    Twitter
    LinkedIn
    Facebook
    Email
    WhatsApp